AB0104 CORRELATION OF PLASMA 14-3-3Η LEVELS WITH DISEASE ACTIVITY MEASURES IN METHOTREXATE-NAÏVE RA PATIENTS TREATED WITH UPADACITINIB MONOTHERAPY IN THE SELECT-EARLY PHASE 3 STUDY
Sornasse, T., Chahal, S., Gui, Y., Nagarajan, N., Friedman, A., Biln, N.
Published in Annals of the rheumatic diseases (01.06.2020)
Published in Annals of the rheumatic diseases (01.06.2020)
Get full text
Journal Article
THU0131 Levels of cxcl13 and sicam1 correlate with disease activity score in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ)
Sornasse, T., Gabay, C., Townsend, M., Laubender, R., Wang, J., Tuckwell, K.
Published in Annals of the rheumatic diseases (01.06.2018)
Published in Annals of the rheumatic diseases (01.06.2018)
Get full text
Journal Article
POS0920 TARGETED SERUM PROTEOMIC ANALYSIS FOLLOWING UPADACITINIB TREATMENT IN ANKYLOSING SPONDYLITIS SHOWS ROBUST SUPPRESSION OF INNATE AND ADAPTIVE IMMUNE PATHWAYS WITH TISSUE REPAIR MODULATION
Sornasse, T., Song, I. H., Radstake, T., Mcgonagle, D.
Published in Annals of the rheumatic diseases (01.06.2021)
Published in Annals of the rheumatic diseases (01.06.2021)
Get full text
Journal Article
POS1133 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH UPADACITINIB RESULTS IN THE COORDINATED INHIBITION OF TYPE 1 IFN-RELATED BIOMARKERS: BIOMARKER ANALYSIS OF THE M19-130 (SLEEK) PHASE 2 STUDY
Gaudreau, M C, Fann, J, Contrepois, S, Friedman, A, Sornasse, T, Merrill, J T
Published in Annals of the rheumatic diseases (01.06.2023)
Published in Annals of the rheumatic diseases (01.06.2023)
Get full text
Journal Article
FRI0026 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB AND ADALIMUMAB HEAD TO HEAD IN RA IDENTIFIES NOVEL, DISCRETE EARLY IMMUNE PATHWAY MODULATION IN THE SELECT-COMPARE PHASE 3 STUDY
Sornasse, T., Song, I. H., Radstake, T., Mcinnes, I.
Published in Annals of the rheumatic diseases (01.06.2020)
Published in Annals of the rheumatic diseases (01.06.2020)
Get full text
Journal Article
OP0024 DIFFERENTIATION BETWEEN IL-6 AND IL-17 PATHWAY INHIBITION IN RELATIONSHIP WITH CLINICAL OUTCOMES IN NON-BIOLOGICAL DMARD-IR AND BIOLOGICAL DMARD-IR PSORIATIC ARTHRITIS PATIENTS TREATED WITH UPADACITINIB IN SELECT-PsA 1 AND SELECT-PsA 2 STUDIES
Cai, F., Sornasse, T., Ruzek, M., Fang, Y., Kato, K., Wung, P., McInnes, I.
Published in Annals of the rheumatic diseases (01.06.2022)
Published in Annals of the rheumatic diseases (01.06.2022)
Get full text
Journal Article
POS0692 RHEUMATOID ARTHRITIS PATIENTS WHO SWITCHED TREATMENT FROM ADALIMUMAB TO UPADACITINIB DEMONSTRATE A ROBUST REDUCTION OF INFLAMMATION-RELATED BIOMARKERS: PROTEOMICS ANALYSIS FROM THE SELECT-COMPARE PHASE 3 STUDY
Sornasse, T., Cai, F., Camp, H., Song, I. H., Mcinnes, I.
Published in Annals of the rheumatic diseases (01.06.2022)
Published in Annals of the rheumatic diseases (01.06.2022)
Get full text
Journal Article
POS0541 PREDICTORS OF REMISSION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH UPADACITINIB OR ADALIMUMAB IN THE SELECT-COMPARE PHASE 3 STUDY: CLINICAL STATUS AT WEEK 12, BUT NOT STANDARD LABORATORY MEASURES, PROVIDES THE BEST CURRENT PREDICTOR OF REMISSION AT WEEK 26
Sornasse, T., Cai, F., Hong, F., Anyanwu, S., Song, I. H., Bukhari, M.
Published in Annals of the rheumatic diseases (01.06.2022)
Published in Annals of the rheumatic diseases (01.06.2022)
Get full text
Journal Article
POS1111 TREATMENT WITH UPADACITINIB RESULTS IN THE INHIBITION OF A BROAD RANGE OF POTENTIALLY PATHOGENIC PATHWAYS IN NR-AXSPA AND BDMARD-IR AS PATIENTS: PROTEOMIC ANALYSIS FROM THE SELECT-AXIS 2 PHASE 3 STUDIES
Sornasse, T, Song, I H, Wung, P, Y Bi, Ravishankar, B, Hu, H A, Maksymowych, W P
Published in Annals of the rheumatic diseases (01.06.2023)
Published in Annals of the rheumatic diseases (01.06.2023)
Get full text
Journal Article
OP0030 TREATMENT OF NON-BIOLOGIC-DMARD-IR PSA PATIENTS WITH UPADACITINIB OR ADALIMUMAB RESULTS IN THE MODULATION OF DISTINCT FUNCTIONAL PATHWAYS: PROTEOMICS ANALYSIS OF THE SELECT-PSA 1 PHASE 3 STUDY
Sornasse, T., Anderson, J., Kato, K., Lertratanakul, A., Ritchlin, C. T., McInnes, I.
Published in Annals of the rheumatic diseases (01.06.2021)
Published in Annals of the rheumatic diseases (01.06.2021)
Get full text
Journal Article
POS0407 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB BETWEEN NON-BIOLOGIC-DMARD-IR AND BIOLOGIC-DMARD-IR PsA PATIENTS IDENTIFIES DISTINCT PATHOGENIC PATHWAYS IN THE SELECT-PsA 1 AND SELECT-PsA 2 PHASE 3 STUDIES
Sornasse, T., Anderson, J., Kato, K., Lertratanakul, A., McInnes, I., Ritchlin, C. T.
Published in Annals of the rheumatic diseases (01.06.2021)
Published in Annals of the rheumatic diseases (01.06.2021)
Get full text
Journal Article
OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Merrill, J T, Tanaka, Y, D D’cruz, Vila, K, Siri, D, Zeng, X, K D’silva, Cheng, L, Sornasse, T, Doan, T, Kruzikas, D, Friedman, A
Published in Annals of the rheumatic diseases (01.06.2023)
Published in Annals of the rheumatic diseases (01.06.2023)
Get full text
Journal Article
NK cell regulation of T cell-mediated responses
Zingoni, Alessandra, Sornasse, Thierry, Cocks, Benjamin G., Tanaka, Yuetsu, Santoni, Angela, Lanier, Lewis L.
Published in Molecular immunology (01.02.2005)
Published in Molecular immunology (01.02.2005)
Get full text
Journal Article
Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
Flamand, V, Sornasse, T, Thielemans, K, Demanet, C, Bakkus, M, Bazin, H, Tielemans, F, Leo, O, Urbain, J, Moser, M
Published in European journal of immunology (01.03.1994)
Published in European journal of immunology (01.03.1994)
Get more information
Journal Article